• Jorge I F Salluh, Pedro Póvoa, Márcio Soares, Hugo C Castro-Faria-Neto, Fernando A Bozza, and Patrícia T Bozza.
• Intensive Care Unit, Instituto Nacional de Câncer, Rio de Janeiro, Brazil, Praça Cruz Vermelha, 23, 10 andar - Centro, 20230-130 - Rio de Janeiro - RJ. jorgesalluh@yahoo.com.br
• Crit Care. 2008 Jan 1;12(3):R76.

IntroductionThe purpose of this review was to evaluate the impact of corticosteroids on the outcomes of patients with severe community-acquired pneumonia (CAP).MethodsWe performed a systematic MEDLINE, Cochrane database, and CINAHL search (1966 to November 2007) to identify full-text publications that evaluated the use of corticosteroids in CAP.ResultsAn initial literature search yielded 109 articles, and 105 studies were excluded after the first analysis. We found four studies eligible for analysis. On the basis of their results, the use of corticosteroids as adjunctive therapy in severe CAP should be categorized as a weak recommendation (two studies) and a strong recommendation (two studies) with either low- or moderate-quality evidence. However, no evidence of adverse outcomes or harm is present in the evaluated studies.ConclusionAccording to the GRADE system, available studies do not support the recommendation of corticosteroids as a standard of care for patients with severe CAP. Further randomized controlled trials with this aim should enroll a larger number of severely ill patients. However, in patients needing corticosteroids, it may be reasonable to conclude that corticosteroid administration is safe in patients with severe infections receiving antimicrobial therapy.

15 keywords...

hide…